Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.48 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2022961 | 0.98 | LOXL2 (0.48) | LOXL2TAAR1UHRF1CYP1A2CYP2A6 | |
| SCHEMBL12288701 | 0.88 | HRH1 (0.46) | LOXL2TAAR1UHRF1CYP2A6KCNQ2 | |
| SCHEMBL4355540 | 0.87 | UHRF1 (0.54) | LOXL2UHRF1KCNQ2LOX | |
| SCHEMBL668247 | 0.83 | — | — | |
| SCHEMBL4358691 | 0.83 | UHRF1 (0.50) | LOXL2UHRF1KCNQ2ALOX15LOX | |
| SCHEMBL14197628 | 0.82 | SIGMAR1 (0.50) | LOXL2UHRF1KCNQ2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5083664 | 0.81 | LOXL2 (0.55) | LOXL2UHRF1KCNQ2LOX | |
| SCHEMBL487318 | 0.81 | UHRF1 (0.48) | UHRF1KCNQ2KDM4ELMNA | |
| SCHEMBL10157627 | 0.81 | GSK3A (0.42) | UHRF1DRD2DRD4DRD3 | |
| SCHEMBL31649652 | 0.80 | UHRF1 (0.43) | LOXL2UHRF1KCNQ2KDM4ELOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1928833-B1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-1928833-A1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| WO-2007039220-A1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | LOXL2 1446/4885TAAR1 1545/4885UHRF1 4774/4885 |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | LOXL2 1757/4885TAAR1 1323/4885UHRF1 4706/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | LOXL2 4148/4885TAAR1 3305/4885UHRF1 622/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | LOXL2 1420/4885TAAR1 1356/4885UHRF1 4824/4885 |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | CNR2, CNR1, GPR52 | LOXL2 2829/4885TAAR1 212/4885UHRF1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.